de Tullio Pascal, Becker Bénédicte, Boverie Stéphane, Dabrowski Michael, Wahl Philip, Antoine Marie-Hélène, Somers Fabian, Sebille Sophie, Ouedraogo Raogo, Hansen John Bondo, Lebrun Philippe, Pirotte Bernard
Centre de Recherche en Pharmacochimie des Substances Naturelles et Synthétiques, Laboratoire de Chimie Pharmaceutique, Université de Liège, 1, Avenue de l'Hôpital, CHU, Tour 4, B-4000 Liège, Belgium.
J Med Chem. 2003 Jul 17;46(15):3342-53. doi: 10.1021/jm021117w.
3-(Alkylamino)-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides were synthesized, and their activity on rat-insulin-secreting cells and rat aorta rings was compared to that of the K(ATP) channel activators diazoxide and pinacidil. Structure-activity relationships indicated that an improved potency and selectivity for the pancreatic tissue was obtained by introducing a fluorine atom in the 7-position and a short linear (preferably ethyl) or cyclic (preferably cyclobutyl) hydrocarbon chain on the nitrogen atom in the 3-position. By contrast, strong myorelaxant activity was gained by the introduction of a halogen atom different from the fluorine atom in the 7-position and a bulky branched alkylamino chain in the 3-position. Thus, 3-(ethylamino)-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide (11) expressed a marked inhibitory activity on pancreatic B-cells (IC(50) = 1 microM) associated with a weak vasorelaxant effect (ED(50) > 300 microM), whereas 7-chloro-3-(1,1-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide (27), which was only slightly active on insulin-secreting cells (IC(50) > 10 microM), was found to be very potent on vascular smooth muscle cells (ED(50) = 0.29 microM). Radioisotopic and electrophysiological investigations performed with 7-chlorinated, 7-iodinated, and 7-fluorinated 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides confirmed that the drugs activated K(ATP) channels. The present data revealed that subtle structural modifications of 3-(alkylamino)-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides can generate original compounds activating K(ATP) channels and exhibiting different in vitro tissue selectivity profiles.
合成了3-(烷基氨基)-7-卤代-4H-1,2,4-苯并噻二嗪1,1-二氧化物,并将它们对大鼠胰岛素分泌细胞和大鼠主动脉环的活性与钾离子通道激活剂二氮嗪和匹那地尔的活性进行了比较。构效关系表明,通过在7位引入氟原子以及在3位氮原子上引入短的直链(优选乙基)或环状(优选环丁基)烃链,可提高对胰腺组织的效力和选择性。相比之下,通过在7位引入不同于氟原子的卤原子以及在3位引入庞大的支链烷基氨基链,可获得较强的肌松活性。因此,3-(乙氨基)-7-氟-4H-1,2,4-苯并噻二嗪1,1-二氧化物(11)对胰腺B细胞表现出显著的抑制活性(IC(50)=1 microM),同时伴有较弱的血管舒张作用(ED(50)>300 microM),而7-氯-3-(1,,1-二甲基丙基)氨基-4H-1,2,4-苯并噻二嗪1,1-二氧化物(27)对胰岛素分泌细胞仅有微弱活性(IC(50)>10 microM),但对血管平滑肌细胞却非常有效(ED(50)=0.29 microM)。对7-氯代、7-碘代和7-氟代的3-烷基氨基-4H-1,2,4-苯并噻二嗪1,1-二氧化物进行的放射性同位素和电生理研究证实,这些药物可激活钾离子通道。目前的数据表明,3-(烷基氨基)-7-卤代-4H-1,2,4-苯并噻二嗪1,1-二氧化物的细微结构修饰可产生激活钾离子通道并表现出不同体外组织选择性特征的新型化合物。